Abstract
571Background: The 21-gene assay (Oncotype DX) gives an intermediate recurrence score (RS 18-30 clinical range, 11-25 trial range) for 32-67% of tested patients. The clinical utility of the FDA-cle...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
